Recovery Compound

Larazotide Acetate

Tight-junction regulator developed for celiac disease; reduces intestinal permeability.

Scientific Overview

Larazotide acetate (AT-1001) is an octapeptide zonulin antagonist that prevents tight-junction disassembly in the small intestine. Innovate Biopharmaceuticals advanced it to Phase 3 (CeDLara) as an adjunct for celiac disease but the trial failed its primary endpoint in 2022, and the program was paused. Still studied in long COVID and IBS.

Key Research Benefits

  • Tightens intestinal junctions
  • Reduces leaky-gut markers
  • Studied in celiac disease

Potential Side Effects

Headache
Nausea
Upper respiratory symptoms

Research Protocols

Common Dosages

Celiac (research)

0.5 mg
3x daily, oral

Before meals

Note: Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Dose Calculator

🧮 Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

20 Units

or 0.20 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Explore Larazotide Acetate

Where to source

Vendors with public COAs that stock this category. Affiliate links are disclosed.

  • Limitless Life Nootropics
    FL-based research-peptide supplier with Janoshik third-party COAs and a public affiliate program at ~20%.
    COA: JanoshikAffiliate disclosed
  • SwissChems
    60+ peptide catalog with Janoshik COAs; weekly affiliate payouts.
    COA: JanoshikAffiliate disclosed
  • Amino Club
    EU/US-facing vendor with a 20% first-order / 10% recurring affiliate model.
    COA: Third-partyAffiliate disclosed

Stack Larazotide Acetate with…

Curated stacking partners researched alongside Larazotide Acetate. Each link opens a dedicated stack page with combined benefits, side-effect overlap, and half-life considerations.

Larazotide Acetate by goal

Read Larazotide Acetate's profile filtered through specific research goals.

Molecular Profile

linear
C39H56N10O15
8 AA Sequence

Quick Reference

Status
Research Compound
Category
Recovery
Common Dosage
0.5 mg
3x daily, oral

Strictly for research purposes. Not for human consumption.

Medical Disclaimer

Information provided on DoseVault is for educational and research purposes only. This website does not advocate for the human use of peptides. Peptides are currently sold as research chemicals and are not FDA-approved for human consumption. Always consult a licensed medical professional before considering any protocol.